DENVER, Colo. (247marketnews.com) -- bioAffinity Technologies (NASDAQ:BIAF) has reached the third day of a sharp post-news advance, and the trading action is beginning to look less like a one-day headline reaction and more like a developing momentum event. With BIAF trading around $11.90 at publication, traders are watching whether the stock can convert this latest burst of interest into a technical breakout and whether short sellers caught leaning against the move could become an additional source of buying pressure.
The immediate technical map is straightforward. $11.71 is the near-term support zone, essentially sitting at the current price, while $14.34 represents the first major trigger level. A decisive move through $14.34 accompanied by expanding volume would provide a much stronger technical signal than a price-only breakout. Above that, the current $18.28 target zone represents roughly 54% upside from $11.90. Those levels should be viewed as trading reference points rather than predictions: in a low-float, small-cap biotech, volume and liquidity can change the character of a move very quickly. Click here for live data.
The more interesting question is why the market is suddenly willing to pay attention to BIAF again. The answer begins with the September 1 announcement that bioAffinity is advancing the potential use of its CyPath Lung test into surveillance of lung-cancer survivors. The company says more than 680,000 Americans were living with a history of lung cancer as of January 1, 2025, creating a substantial population that requires ongoing surveillance. CyPath Lung is already positioned around noninvasive assessment of patients at high risk for lung cancer; extending the potential application into the post-treatment surveillance market gives investors another way to think about the company's addressable opportunity.
The announcement does not mean CyPath Lung has suddenly been clinically validated as a recurrence-surveillance test. Rather, bioAffinity is advancing a potential application based on the clinical problem physicians face when imaging identifies new or changing pulmonary nodules after treatment. The company points out that CT imaging may not readily distinguish recurrent cancer, a new primary cancer or benign changes such as fibrosis, scarring and treatment-related inflammation. Texas Oncology physician Vijay Gunuganti, MD, put the problem bluntly: “Imaging alone cannot tell us if it is recurrent cancer, a new cancer, or benign post-treatment changes including fibrosis, scarring, and treatment-related inflammation.”
For traders, however, the announcement becomes more interesting when placed beside BIAF's existing commercial momentum. In its second-quarter report, bioAffinity said CyPath Lung test volume increased 216% year over year. Management also said physician adoption was accelerating and that the company was advancing a longitudinal clinical trial. CEO Maria Zannes said the commercial strategy was gaining traction as physicians recognized CyPath Lung's potential value for both high-risk patients and surveillance of lung-cancer survivors.
The company has also been layering additional commercial channels onto that story. In August, bioAffinity announced a nationwide federal healthcare distribution agreement with AvMEDICAL, giving CyPath Lung another potential route into government healthcare systems, including the Department of Veterans Affairs. The company's regulatory and commercial strategy is therefore becoming broader: physician adoption, government distribution, longitudinal clinical development and now an explicitly articulated survivorship opportunity.
That is the fundamental reason this particular news release has more potential staying power than a typical promotional headline. The market is not being asked to digest just one isolated data point. Investors are being presented with a narrative in which a diagnostic already generating commercial activity could potentially serve multiple points along the lung-cancer continuum. Whether that ultimately translates into significant revenue remains to be demonstrated, but it gives momentum traders a fundamental story to trade against.
The Short-Squeeze Question
This is where the BIAF setup gets particularly interesting, but also where discipline matters.
A three-day advance can create the conditions for a squeeze if a stock has meaningful short positioning, limited readily available shares and increasing demand. As the stock rises, traders who sold short must eventually decide whether to maintain their positions or buy shares to cover. If buying pressure forces the price through technical resistance, additional short covering can add fuel to the move. Momentum traders can then pile into the breakout, creating a feedback loop of price → volume → short covering → more price momentum.
However, it is important not to confuse that mechanism with proof that BIAF is currently experiencing a short squeeze. A genuine squeeze thesis requires current short-interest and trading-volume data, and those metrics can change rapidly. The safer conclusion is that BIAF's price action may be creating conditions in which short covering could amplify an already-established momentum move.
There is another unusual factor: BIAF recently underwent a 1-for-15 reverse stock split, effective for trading on August 24. bioAffinity said the action was primarily intended to address Nasdaq's minimum-bid-price requirement. The company had previously disclosed that Nasdaq had notified it of noncompliance after the stock traded below $1 for 30 consecutive business days and that it had appealed the determination.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.